Company Overview
Company Type: Public Company
Website: www.biomindlabs.com
Number of Employees: 5
Ticker: BMND.F (OTCPK)
Year Founded: -


Business Description
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; and BMND08, a 5-Methoxy-N,N-dimethyltryptamine based candidate that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer’s-type cognitive impairment. It is also developing new and preclinical drug candidates, including BMND02 for treating fibromyalgia, BMND03 for treating addictive disorders, BMND05 for treating chronic pain, BMND06 for treating inflammatory disorders, and BMND07 for treating major depressive disorder. The company is headquartered in Canelones, Uruguay.

Financial Information (Currency: CAD, in mm) 
EBITDA
(3.6)
EBIT
(3.6)
Cash & ST Invst.
0.0
Net Income
(3.6)
Total Debt
0.0
Total Assets
0.1
Currency in CAD in mm, LTM as of Mar-31-2023 TEV and Market Cap are calculated using a close price as of Feb-13-2023

Key Professionals
Name
Title
Antalich, Alejandro 
CEO & Director
Leon, Oscar Alejandro
CFO & Director
Dellavalle, Paola Diaz
Chief Scientific Officer
Presa, Juan 
Chief Legal Officer
Alvarez, Magdalena 
Head of Communication
Daners, Martin 
Head of Quality Assurance & Regulatory Affairs

Key Board Members
Name
Title
Sood, Ravi
Chairman of the Board
Antalich, Alejandro 
CEO & Director
Leon, Oscar Alejandro
CFO & Director
Buchan, Fraser Alexander
Director
Illigens, Ben M. W.
Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
Building Ceibo Of. 002 Camino Saravia s/n 91.000, Pando | Canelones | Uruguay

Current and Pending Investors
Negev Capital, Union Acquisition Group, LLC


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Liverdome Development Inc.
Liverdome Development Inc. is based in BVI. As of December 30, 2020, Liverdome Development Inc. operates as a subsidiary of Biomind Labs Inc.

Latin America and Caribbean
-
-
-
-
Crosswinds Holdings Inc.
Biomind Research Corp. acquired Crosswinds Holdings Inc. in a reverse merger transaction on July 23, 2021. Crosswinds Holdings Inc., formerly known as C.A. Bancorp Inc., is a private equity firm specializing in management buyouts, acquisitions, expansions, restructurings, leveraged buy-out, refinancing, distressed securities, bankruptcy exits, growth capital, turnarounds, PIPE transactions of middle-market companies, and other alternative investment opportunities. The firm focuses its investments in small and middle capitalization public and private companies. It also participates in open market purchases, equity investments in private issuers, and privatization of public companies. The firm seeks to invest in industrials, real estate, infrastructure, asset management, and financial services with a particular focus on the insurance industry including reinsurance. Within industrials, it seeks to invest in mature industrial companies with a focus on manufacturing, distribution, and service sectors. Its infrastructure investment opportunities focus on power generation, transportation, and utilities. The firm’s investment in real estate includes industrial, commercial, healthcare, hospitality, and retail properties. Within financial services, it invests in Canadian and international financial services businesses, including asset managers and investment counselors. The firm also invests in electric power generation by nuclear fuels and fossil fuels. From time to time, it will seek to invest in Capital Pool Companies within the real estate, infrastructure, and other asset-rich areas. The firm seeks to invest in the undervalued North American private and public companies based in Canada and the Unites States. Its public investments will focus on mid-market companies trading on the Toronto Stock Exchange. It typically invests between $0.5 million and $20 million in companies with enterprise values between $25 million and $200 million. The firm seeks to pursue investments that offer returns between 1.5 percent and three percent. The firm has a preference for dislocations and underfollowed sectors of the market. It seeks a board seat in its portfolio companies. The firm exits its investments through sale to strategic buyers or financial investors, open market sales, normal course retirement of securities, refinancing, and public offerings. Crosswinds Holdings Inc. is based in Toronto, Canada with an additional office in New York, New York.

United States and Canada
Asset Management and Custody Banks
0.00
0.00
0.00


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Apr-27-2023
Apr-14-2023
Merger/Acquisition
Target
Biomind Labs Inc. (OTCPK:BMND.F)

Union Acquisition Group, LLC
14.18
Dec-17-2021
-
Shelf Registration
Target
Biomind Labs Inc. (OTCPK:BMND.F)


75.00
Jun-29-2021
Dec-30-2020
Merger/Acquisition
Buyer
Liverdome Development Inc.
Biomind Labs Inc. (OTCPK:BMND.F)

-
Feb-22-2021
Jul-09-2021
Private Placement
Target
Biomind Labs Inc. (OTCPK:BMND.F)


4.96
Feb-22-2021
Jul-23-2021
Merger/Acquisition
Buyer
Crosswinds Holdings Inc.
Biomind Labs Inc. (OTCPK:BMND.F)

3.76
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-14-2023
Product-Related Announcements
Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications
Jun-28-2023
Annual General Meeting
Biomind Labs Inc., Annual General Meeting, Jun 28, 2023
Jun-28-2023
Shareholder/Analyst Calls
Biomind Labs Inc. - Shareholder/Analyst Call
Apr-27-2023
M&A Transaction Closings
An unknown buyer acquired 27.09% stake in Biomind Labs Inc. (OTCPK:BMND.F) from Union Acquisition Group, LLC for $14.1 million.
Apr-25-2023
Product-Related Announcements
Biomind Labs Inc. Announces the Start of the First-Ever Clinical Trial Targeting Depression and Anxiety in Alzheimer’S Disease with A Proprietary Formulation Based on 5-Meo-Dmt


Advisors
Most Recent Auditor
MNP LLP
Private Placement Advisors
Canaccord Genuity Corp.


Most Recent Auditor
Meyers Norris Penny LLP - MNP LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Jul 01, 2021 04:13 AM
BMND.F
Crosswinds Holdings Inc 2021_07_01
Reports
14
S&P Global Compustat

Jun 03, 2021 03:34 AM
BMND.F
Crosswinds Holdings Inc 2021_06_03
Reports
14
S&P Global Compustat

May 06, 2021 04:05 AM
BMND.F
Crosswinds Holdings Inc 2021_05_06
Reports
14
S&P Global Compustat

Apr 01, 2021 03:51 AM
BMND.F
Crosswinds Holdings Inc 2021_04_01
Reports
14
S&P Global Compustat

Mar 04, 2021 03:33 AM
BMND.F
Crosswinds Holdings Inc 2021_03_04
Reports
14
S&P Global Compustat

Feb 04, 2021 03:43 AM
BMND.F
Crosswinds Holdings Inc 2021_02_04
Reports
14
S&P Global Compustat

Jan 07, 2021 02:51 AM
BMND.F
Crosswinds Holdings Inc 2021_01_07
Reports
14
S&P Global Compustat

Dec 03, 2020 02:52 AM
BMND.F
Crosswinds Holdings Inc 2020_12_03
Reports
14
S&P Global Compustat

Nov 05, 2020 03:00 AM
BMND.F
Crosswinds Holdings Inc 2020_11_05
Reports
14
S&P Global Compustat

Oct 01, 2020 02:59 AM
BMND.F
Crosswinds Holdings Inc 2020_10_01
Reports
14



Top Buyers
No Top Buyers data available.

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Jose-Pineyro Sartori CFA, Juan 
0
(50,000,000)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
BMND01 (Future), BMND02 (Future), BMND03 (Future), BMND05 (Future), BMND06 (Future), BMND07 (Future), BMND08 (Future)


Upcoming Events
Date/Time
Type
Nov-14-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
May-15-2023
Mar-31-2023
Biomind Labs Inc. (OTCPK:BMND.F)
SEDAR
Interim Financial Statements
307 KB
Mar-31-2023
Dec-31-2022
Biomind Labs Inc. (OTCPK:BMND.F)
SEDAR
Annual Financial Statements
1 MB
Nov-14-2022
Sep-30-2022
Biomind Labs Inc. (OTCPK:BMND.F)
SEDAR
Interim Financial Statements
318 KB
Aug-15-2022
Jun-30-2022
Biomind Labs Inc. (OTCPK:BMND.F)
SEDAR
Interim Financial Statements
310 KB
May-16-2022
Mar-31-2022
Biomind Labs Inc. (OTCPK:BMND.F)
SEDAR
Interim Financial Statements
131 KB
Mar-31-2022
Dec-31-2021
Biomind Labs Inc. (OTCPK:BMND.F)
SEDAR
Annual Financial Statements
727 KB
Aug-16-2021
Jun-30-2021
Biomind Labs Inc. (OTCPK:BMND.F)
SEDAR
Interim Financial Statements
165 KB

Key Board Members Details
Name
Title
Phone
Fax
Email
Sood, Ravi
Chairman of the Board
-
-
Ravi@GalaneGold.com
Antalich, Alejandro 
CEO & Director
+358 50 5512 848
-
alejandro.antalich@evokailabs.com
Leon, Oscar Alejandro
CFO & Director
-
-

Buchan, Fraser Alexander
Director
(416) 473-4099
-
fbuchan@83yonge.com
Illigens, Ben M. W.
Director
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Antalich, Alejandro 
CEO & Director
+358 50 5512 848
-
alejandro.antalich@evokailabs.com
Leon, Oscar Alejandro
CFO & Director
-
-

Dellavalle, Paola Diaz
Chief Scientific Officer
-
-

Presa, Juan 
Chief Legal Officer
-
-

Alvarez, Magdalena 
Head of Communication
-
-

Daners, Martin 
Head of Quality Assurance & Regulatory Affairs
-
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
